Cannatrek’s Shepparton facility achieves GMP accreditation 

Cannabiz reports that Cannatrek has received Good Manufacturing Practice (GMP) accreditation from the Therapeutic Goods Administration for its $5 million manufacturing facility in Shepparton. This achievement, described by CEO Tommy Huppert as a ‘major milestone’, will enhance in-house production capabilities and is part of a larger $17 million investment plan by Cannatrek in the Shepparton region. Over the next three years, the company projects to create more than 70 jobs in regional Victoria and expand manufacturing prospects. Additionally, the GMP certification will bolster export potential, facilitating smoother access to global markets. 

Read more:

Information about studies provided by Cannatrek on this website is for education purposes only. It is not a substitute for professional health advice. Nothing contained in this site, or any external site linked to by Cannatrek, is intended to be used as medical advice and it is not intended to be used to diagnose, treat, cure or prevent any disease, nor should it be used for therapeutic purposes or as a substitute for your own health professional’s advice. Cannatrek does not accept any liability for any injury, loss or damage incurred by use of or reliance on the information provided on this website, or any external site linked to by Cannatrek. Further, Cannatrek accepts no responsibility for material contained in a website that is linked to this site. It is the responsibility of the user to make their own decisions about the accuracy, currency, reliability and correctness of information contained in linked external websites.